SITE006-0123

SITE006 (GBR) › SITE006-0123

SITE006-0123

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE006 (GBR) · Dr. Rossi
consented 2026-01-27

completed

AEs

4

Serious

0

Dropout signal

–

Adverse events

4

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-04 (study day 61); relationship: not assessed

moderate assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-09-19 (study day 46); relationship: not assessed

moderate assessed

Grade 3 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-09-08 (study day 35); relationship: not assessed

severe assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-08-24 (study day 20); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.